Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Apitoxin is a new biological drug for pain & inflammation and arthritis, approved by the Korean FDA on May 3, 2003 after 14 years of preclinical, animal, and phase I, II & III clinical studies More
Ob-X is composed of herbal extracts, and reduced body and adipose tissue weight and number and size of lipid vacuoles in the liver in animal studies; reduced body weight, waist circumference and visceral fat in human studies More
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Improving the reconstitution and increasing the stability of biomolecules using supercritical fluid (SCF) processing More
These hybrid antibody molecules can be engineered with a variety of small synthetic molecules, and the combination of immunogenic properties results in compounds with powerful target destruction or imaging capabilities. More
Cardiovascular physiology and atherosclerosis - prevention of cardiovascular complications in patients with renal failure or increased carbamylation. More
Precise and focused control of temperature mediated therapy and “triggering” deliverables in situ. More
An siRNA type therapeutics delevary system More
Novel agents capable of reaching remote cellular sites More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 68 pages - $600
Nov 2010 - 56 pages - $600
Nov 2010 - 92 pages - $600
Nov 2010 - 179 pages - $600
Nov 2010 - 60 pages - $600
Nov 2010 - 49 pages - $600
Nov 2010 - 259 pages - $600
Nov 2010 - 105 pages - $600
Nov 2010 - 106 pages - $600
Sep 2010 - 57 pages - $350
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us